Results 91 to 100 of about 1,470 (198)

Ravulizumab and Efgartigimod in Myasthenia Gravis

Neurology Neuroimmunology & Neuroinflammation
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, Malina Behrens, Christian W. Keller, Luisa Klotz, Sophie Lehnerer, Maike Stein, Meret Herdick, Paolo Doksani, Lea M. Gerischer, Sarah Hoffmann, Konstantinos Lazaridis, John Tzartos, Heinz Wiendl, Andreas Meisel, Jan D. Lünemann   +16 more
openaire   +4 more sources

Open-label study of efgartigimod in seronegative myasthenia gravis

Therapeutic Advances in Neurological Disorders
Background: The ADAPT trial demonstrated the benefit of efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, in acetylcholine receptor antibody (AChRAb) positive patients with generalized myasthenia gravis (MG).
Mohamed Khateb, Ajith Sivadasan, Carolina Barnett-Tapia, Lubna Daniyal, Lahiru Fernando, Shiyi Chen, Leif Erik Lovblom, Hans Katzberg, Vera Bril   +8 more
doaj   +1 more source

Efgartigimod-associated Kaposi’s varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review

Frontiers in Immunology
BackgroundEfgartigimod (Efgartigimod alpha fcab, Vyvgart™) is a pioneering neonatal Fc receptor (FcRn) antagonist for the treatment of severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG) autoantibodies, including myasthenia gravis ...
Lingzhi Ge, Yanyan Li, Ying Sun, Wenfang Chen, Xiaoli Ni, Xiaoli Ni, Fangli Wei, Zhen Mu   +7 more
doaj   +1 more source

Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report [PDF]

BackgroundThymectomy is one of the main treatments for thymoma associated myasthenia gravis, but there is a risk of acute exacerbation of myasthenia gravis symptoms during the perioperative period of thymoma.
Anguo Chen, Hongru Li, Juanjuan Zhang, Ling Wei, Liuli Ren, Song Jiang   +5 more
core   +1 more source

Efgartigimod Alfa-fcab

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study

Neurotherapeutics
Early intervention in impending myasthenic crisis (IMC) is critical to avert life-threatening progression. This study compared the clinical effectiveness and safety of the novel FcRn antagonist efgartigimod versus intravenous immunoglobulin (IVIg) in IMC
Rongjing Guo, Chao Sun, Xiaoxi Huang, Sijia Hao, Qingqing Wang, Zhe Ruan, Ting Gao, Yonglan Tang, Xiangqi Cao, Yu Liu, Zhuyi Li, Ting Chang   +11 more
doaj   +1 more source

Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study. [PDF]

BACKGROUND: Thymoma-associated myasthenia gravis (TAMG) is a subtype of myasthenia gravis (MG) that is associated with more severe symptoms and a relatively poor prognosis.

core   +1 more source

Ocular Myasthenia Gravis; a Case Report [PDF]

Background: Myasthenia gravis (MG) is an autoimmune disease disorder that affects the skeletal muscles causing increased fatigability and weakness. When it affects the ocular muscles only, it is known as ocular myasthenia gravis (OMG).
Garbo Maxey, Amy, OD, Wilson, Kristin, OD   +1 more
core   +1 more source

Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy : A randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study [PDF]

Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by weakness and sensory loss. We assessed the neonatal Fc receptor inhibitor rozanolixizumab for CIDP management.
Bozorg, A., Colson, A.O., De Sèze, J., Dysgaard, T., Eftimov, F., Hartung, H.P., Kiessling, P., Levine, T., Marmol, D., Massow, U., Querol, Luis, Rao, T.H., Rivner, M., Shimizu, S., Universitat Autònoma de Barcelona   +14 more
core   +1 more source

Sequential administration of efgartigimod shortened the course of Guillain–Barré syndrome: a case series

Therapeutic Advances in Neurological Disorders
Guillain–Barré syndrome (GBS) is a serious neurological condition with limited treatment options. A recent report demonstrated successful treatment with efgartigimod alone in two patients with GBS, although it did not significantly shorten the disease ...
Sihui Chen, Ruwei Ou, Qianqian Wei, Bi Zhao, Xueping Chen   +4 more
doaj   +1 more source